Recently FDA approved pediatric suspension of VESIcare for used in pediatric patients aged 2 years and older for the treatment of:
a. Overactive bladder
b. Neurogenic detrusor overactivity
c. Nausea and vomiting
d. Preventing excessive gastrin secretion
e. Diarrhea associated with C. difficile
The active ingredient found in VESIcare is Solifenacin succinate. It is a muscarinic antagonist. It is available in tablet and pediatric oral suspension dosage forms.
VESIcare LS oral suspension will come in a 5 mg/5 mL (1 mg/mL) oral suspension and will be available in the United States in late 2020.
The tablet dosage form is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
The recommended dose is 5 to 10 mg orally once daily.
Recently, Food and Drug Administration (FDA) has approved VESIcare LS (Solifenacin succinate) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 2 years and older.
Patients with NDO may experience involuntary bladder contractions, which can lead to symptoms of urinary urgency, frequency and incontinence. Spina bifida, a congenital spinal cord defect, is a common cause of NDO in children.
The most common adverse reactions (more than 4% in VESIcare-treated patients and placebo-treated patients) were dry mouth and constipation at both 5 mg and 10 mg doses; and urinary tract infection and blurred vision at the 10 mg dose.
www.pharmacyexam.com Try our Naplex Questions QBank.